[go: up one dir, main page]

MA53219B1 - Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase - Google Patents

Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase

Info

Publication number
MA53219B1
MA53219B1 MA53219A MA53219A MA53219B1 MA 53219 B1 MA53219 B1 MA 53219B1 MA 53219 A MA53219 A MA 53219A MA 53219 A MA53219 A MA 53219A MA 53219 B1 MA53219 B1 MA 53219B1
Authority
MA
Morocco
Prior art keywords
heterocyclic compounds
novel heterocyclic
lipase inhibitors
monoacylglycerol lipase
compounds
Prior art date
Application number
MA53219A
Other languages
English (en)
Other versions
MA53219A (fr
Inventor
Bernd Kuhn
Katrin Groebke Zbinden
Luca Gobbi
Buelent Kocer
Fionn O`HARA
Carsten KROLL
Uwe Grether
Didier Rombach
Hans Richter
Joerg Benz
Charles Bell
Benoit Hornsperger
Martin Ritter
Marius Daniel Rinaldo LUTZ
Martin KURATLI
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA53219A publication Critical patent/MA53219A/fr
Publication of MA53219B1 publication Critical patent/MA53219B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux composés hétérocycliques de formule générale (I), dans laquelle A, L, X, m, n, R1 et R2 sont tels que décrits dans la description, des compositions comprenant les composés, des procédés de fabrication des composés et des procédés d'utilisation des composés.
MA53219A 2018-08-13 2019-08-12 Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase MA53219B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18188681 2018-08-13
PCT/EP2019/071520 WO2020035424A1 (fr) 2018-08-13 2019-08-12 Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
EP19755855.4A EP3837263B1 (fr) 2018-08-13 2019-08-12 Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase

Publications (2)

Publication Number Publication Date
MA53219A MA53219A (fr) 2021-11-17
MA53219B1 true MA53219B1 (fr) 2024-09-30

Family

ID=63244467

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53219A MA53219B1 (fr) 2018-08-13 2019-08-12 Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase

Country Status (33)

Country Link
US (3) US20200308190A1 (fr)
EP (2) EP4474017A3 (fr)
JP (2) JP7637049B2 (fr)
KR (1) KR102879259B1 (fr)
CN (1) CN112867720A (fr)
AR (1) AR116666A1 (fr)
AU (1) AU2019322538B2 (fr)
BR (1) BR112021002298A2 (fr)
CA (1) CA3104928A1 (fr)
CL (1) CL2021000362A1 (fr)
CO (1) CO2021002382A2 (fr)
CR (1) CR20210077A (fr)
DK (1) DK3837263T3 (fr)
ES (1) ES2986417T3 (fr)
FI (1) FI3837263T3 (fr)
HR (1) HRP20241201T1 (fr)
HU (1) HUE067912T2 (fr)
IL (1) IL279173B2 (fr)
LT (1) LT3837263T (fr)
MA (1) MA53219B1 (fr)
MX (1) MX2021001433A (fr)
MY (1) MY210507A (fr)
PE (1) PE20211089A1 (fr)
PH (1) PH12021500013A1 (fr)
PL (1) PL3837263T3 (fr)
PT (1) PT3837263T (fr)
RS (1) RS65912B1 (fr)
RU (1) RU2769507C1 (fr)
SG (1) SG11202013064WA (fr)
SI (1) SI3837263T1 (fr)
TW (1) TWI812770B (fr)
UA (1) UA127629C2 (fr)
WO (1) WO2020035424A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
TW201936602A (zh) 2017-11-28 2019-09-16 瑞士商赫孚孟拉羅股份公司 新雜環化合物
CN111566105A (zh) 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
JP7474709B2 (ja) 2018-02-27 2024-04-25 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
HUE067912T2 (hu) * 2018-08-13 2024-11-28 Hoffmann La Roche Új heterociklusos vegyületek, mint monoacil-glicerin-lipáz inhibitorok
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MX2022002720A (es) * 2019-09-05 2022-08-10 Lunan Pharmaceutical Group Corp Inhibidor de magl, procedimiento de preparacion y uso del mismo.
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
CA3151516A1 (fr) * 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag Composes 4,4a,5,7,8,8 a-hexapyrido [4,3-b] [1,4] oxazin-3-one en tant qu'inhibiteurs de magl
WO2021058416A1 (fr) * 2019-09-23 2021-04-01 F. Hoffmann-La Roche Ag Composés hétérocycliques
BR112022005472A2 (pt) * 2019-09-24 2022-06-14 Hoffmann La Roche Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica
US20210094972A1 (en) * 2019-09-24 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
KR20220079880A (ko) 2019-10-07 2022-06-14 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴메틸렌 헤테로시클릭 화합물
JP7729831B2 (ja) * 2020-03-26 2025-08-26 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子としてのアミノシクロブタン
CA3190277A1 (fr) 2020-09-03 2022-03-10 Joerg Benz Composes heterocycliques
US20250084065A1 (en) 2021-12-29 2025-03-13 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
WO2024168426A1 (fr) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Petites molécules utilisées en tant qu'inhibiteurs de monoacylglycérol lipase (magl), compositions et utilisation associées

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
EP1896453B1 (fr) 2005-06-20 2009-12-02 Schering Corporation Pipéridines substituées liées à un atome de carbone et leurs dérivés utiles en tant qu antagonistes de l'histamine h3
CA2627839C (fr) 2005-11-02 2014-08-19 Bayer Healthcare Ag Derives pyrrolo-[2,1-f]-[1,2,4]-triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives
CA2637531A1 (fr) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Composes ayant une affinite pour le recepteur 5-ht6
WO2007117557A2 (fr) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanols inhibiteurs de rénine
KR101805914B1 (ko) 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
FR2915197B1 (fr) * 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
PL2266989T3 (pl) 2008-03-31 2016-04-29 C&C Res Lab Pochodne heterocykliczne
CA2741153A1 (fr) 2008-10-29 2010-05-06 F. Hoffmann-La Roche Ag Nouveaux derives d'amides phenyliques ou d'amides pyridyliques et leur utilisation en tant agonistes de gpbar1
BR112012005382A2 (pt) 2009-09-10 2016-03-29 Hoffmann La Roche inibidores de jak
WO2011059118A1 (fr) 2009-11-10 2011-05-19 Kim Hyun Jeen Système de test de perception olfactive
WO2011058766A1 (fr) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Dérivés d'arylcarboxamide comme bloqueurs de ttx-s
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
WO2013059118A1 (fr) 2011-10-19 2013-04-25 The Trustees Of Columbia University In The City Of New York Compositions catalytiques à base de cyclopropénimine et procédés
WO2013080156A1 (fr) 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd Antibiotiques d'octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one 3,7-disubstituée
DK2794600T3 (en) 2011-12-22 2018-03-12 Novartis Ag -2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
EP2986607B1 (fr) 2013-04-16 2017-06-14 Actelion Pharmaceuticals Ltd. Dérivés biaromatiques antibactériens
WO2016109501A1 (fr) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Composés amides utilisés en tant qu'inhibiteurs de la tryptophane hydroxylase
EP3279191B1 (fr) * 2015-03-30 2020-09-02 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2016180536A1 (fr) 2015-05-13 2016-11-17 Selvita S.A. Dérivés de quinoxaline substitués
BR112017024678A2 (pt) 2015-05-21 2018-07-31 Glaxosmithkline Intellectual Property Development Limited derivados de benzoimidazol como inibidores de pad4
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
WO2017021805A1 (fr) 2015-07-31 2017-02-09 Pfizer Inc. Dérivés de carbamate de 1,1,1-trifluoro-3-hydroxypropan-2-yle et dérivés de carbamate de 1,1,1-trifluoro-4-hydroxybutan-2-yle comme inhibiteurs de magl
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017087863A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2017170830A1 (fr) * 2016-03-31 2017-10-05 武田薬品工業株式会社 Composé hétérocyclique
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
JP2019520372A (ja) 2016-06-30 2019-07-18 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ 増殖性障害の処置のためのミトコンドリア阻害剤
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
HUE064559T2 (hu) 2016-11-16 2024-03-28 H Lundbeck As MAGL inhibitor kristályos formája
PE20200340A1 (es) 2017-06-12 2020-02-14 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de vanina
CN111148746B (zh) 2017-09-29 2022-08-05 武田药品工业株式会社 杂环化合物
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
TW201936602A (zh) 2017-11-28 2019-09-16 瑞士商赫孚孟拉羅股份公司 新雜環化合物
TW201930300A (zh) 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
CN111566105A (zh) 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
ES2942319T3 (es) 2018-03-22 2023-05-31 Hoffmann La Roche Inhibidores de oxacina monoacilglicerol lipasa (MAGL)
WO2020035425A1 (fr) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
HUE067912T2 (hu) 2018-08-13 2024-11-28 Hoffmann La Roche Új heterociklusos vegyületek, mint monoacil-glicerin-lipáz inhibitorok
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
KR20210094540A (ko) 2018-11-22 2021-07-29 에프. 호프만-라 로슈 아게 헤테로사이클릭 화합물
WO2020207941A1 (fr) 2019-04-09 2020-10-15 F. Hoffmann-La Roche Ag Composés hétérocycliques en tant qu'inhibiteurs de la monoacylglycérol lipase (magl)
CR20210630A (es) 2019-07-03 2022-02-11 Hoffmann La Roche Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
KR20220034104A (ko) 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
CA3151516A1 (fr) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag Composes 4,4a,5,7,8,8 a-hexapyrido [4,3-b] [1,4] oxazin-3-one en tant qu'inhibiteurs de magl
WO2021048241A1 (fr) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag Composés radiomarqués
WO2021058416A1 (fr) 2019-09-23 2021-04-01 F. Hoffmann-La Roche Ag Composés hétérocycliques
US20210094972A1 (en) 2019-09-24 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
EP4034602A1 (fr) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG Sondes fluorescentes pour la monoacylglycérol lipase (magl)
BR112022005472A2 (pt) 2019-09-24 2022-06-14 Hoffmann La Roche Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica
JP7785755B2 (ja) 2020-08-26 2025-12-15 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤として有用な複素環化合物
CA3190277A1 (fr) 2020-09-03 2022-03-10 Joerg Benz Composes heterocycliques
CA3215260A1 (fr) 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Composes heterocycliques

Also Published As

Publication number Publication date
IL279173B2 (en) 2025-05-01
US20230050901A1 (en) 2023-02-16
US12281124B2 (en) 2025-04-22
AU2019322538A1 (en) 2021-01-07
MY210507A (en) 2025-09-28
WO2020035424A1 (fr) 2020-02-20
BR112021002298A2 (pt) 2021-05-04
US20200308190A1 (en) 2020-10-01
FI3837263T3 (fi) 2024-09-03
DK3837263T3 (da) 2024-09-09
MA53219A (fr) 2021-11-17
JP2024174966A (ja) 2024-12-17
JP2021534139A (ja) 2021-12-09
IL279173A (en) 2021-01-31
SI3837263T1 (sl) 2024-10-30
ES2986417T3 (es) 2024-11-11
TWI812770B (zh) 2023-08-21
US11802133B2 (en) 2023-10-31
LT3837263T (lt) 2024-09-25
CO2021002382A2 (es) 2021-03-08
CA3104928A1 (fr) 2020-02-20
SG11202013064WA (en) 2021-01-28
RU2769507C1 (ru) 2022-04-01
CR20210077A (es) 2021-03-11
EP4474017A2 (fr) 2024-12-11
PL3837263T3 (pl) 2024-10-14
IL279173B1 (en) 2025-01-01
UA127629C2 (uk) 2023-11-08
TW202021970A (zh) 2020-06-16
CN112867720A (zh) 2021-05-28
CL2021000362A1 (es) 2021-07-09
MX2021001433A (es) 2021-04-12
EP3837263A1 (fr) 2021-06-23
JP7637049B2 (ja) 2025-02-27
HRP20241201T1 (hr) 2024-11-22
AR116666A1 (es) 2021-06-02
PE20211089A1 (es) 2021-06-14
KR102879259B1 (ko) 2025-10-31
HUE067912T2 (hu) 2024-11-28
PH12021500013A1 (en) 2021-09-13
KR20210045992A (ko) 2021-04-27
AU2019322538B2 (en) 2021-09-30
US20240150373A1 (en) 2024-05-09
RS65912B1 (sr) 2024-10-31
EP3837263B1 (fr) 2024-07-03
PT3837263T (pt) 2024-08-30
EP4474017A3 (fr) 2025-02-26

Similar Documents

Publication Publication Date Title
MA53219B1 (fr) Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MA55131B1 (fr) Nouveaux composés hétérocycliques
MA64323B1 (fr) Inhibiteurs de nlrp3
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA48594B1 (fr) Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
MA32391B1 (fr) Activateurs de la glucokinase
MA31597B1 (fr) Nouveaux herbicides
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
HN2006019068A (es) "sintesis de (r)-n-metilnaltrexona"
MA46325A (fr) Composés dinucléotidiques cycliques
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
MA34359B1 (fr) Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA49560B1 (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA45222B1 (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA31596B1 (fr) Nouveaux herbicides
MA31782B1 (fr) Antagonistes du cgrp
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA47085B1 (fr) Polymorphes